TD Cowen Maintains Buy on United Therapeutics, Raises Price Target to $700
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Joseph Thome maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $675 to $700.
TD Cowen analyst Joseph Thome maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $675 to $700.